Press releases, updates and announcements
Smart Matrix clinical data presented at the 101st Annual Meeting of the British Association of Dermatologists
Smart Matrix Limited is pleased to announce that the latest data from its clinical trial assessing Smart Matrix for the treatment of surgical excision wounds is being presented at the 101st Annual Meeting of the British Association of Dermatologists; 6th-8th July 2021 https://badannualmeeting.co.uk. Mr Baljit Dheansa, consultant plastic surgeon and Chief Investigator of the clinical trial, gives a 10 minute oral presentation entitled “Replacing the Need for Skin Grafting in Small Surgical Excision Wounds” in the Special Interest Group Session organized by the British Society for Dermatological Surgery. The presentation highlights the latest exciting results from the ongoing clinical trial in which the Smart Matrix dermal scaffold is being assessed for the treatment of NMSC excision wounds without the use of an overlying skin graft, as summarized in the abstract below.
21 September 2017
21 April 2017
3 April 2017
31 March 2017
20 March 2017
30 January 2017
Andy Hill appointed to the Board.
3 January 2017
Andy Hill joins Smart Matrix Limited as CEO.
Smart Matrix Limited closes another successful fundraising round with £1.3m coming from existing shareholders.
19 May 2016
Appointment of Swen Lorenz to the Board of Smart Matrix Limited.
3 May 2016
Appointment of Mark Brown to the Board of Smart Matrix Limited.
Completed pre-clinical studies at Northwick Park Institute for Medical Research.
31 December 2015
Completion of 12 month follow up to last patient in the clinical trial of Smart Matrix®.
Commenced detailed programme of follow-on pre-clinical studies.
2 April 2015
The Data Monitoring Committee meets and confirms the safety of Smart Matrix®.
24 February 2015
Appointment of Dr Fulvio Urso-Baiarda as Medical Advisor.
26 January 2015
Appointment of Dr Lilian Hook as Chief Scientific Officer to SML.
3 January 2015
Enrolment of the final patient into the clinical trial of Smart Matrix®.
29 October 2014
A new licence agreement is signed with Smart Matrix Intellectual Property Limited extending SML’s intellectual property rights.
19 August 2014
The first patient was treated in the clinical trial of Smart Matrix®.
4 June 2014
A letter with a notification of No Objection was received from the MHRA.
24 April 2014
Application for the pre-clinical assessment of Smart Matrix® – acknowledgement of notification received from the MHRA.
27 March 2014
Completion of £300,000 (net) investment by Reyker Nominees Ltd on behalf of Downing LLP.
23 August 2013
The Company is pleased to report closure of Tranche 2 of its fundraising with equity receipts in excess of £3.4 million.
9 August 2013
First Work Order signed with Clinical Research Organisation (CRO) in contemplation of clinical trials commencement.
3 May 2013
Master Service Agreement signed with our chosen CRO following a thorough selection process.
6 February 2013
Jeremy Curnock Cook appointed to the Board of Smart Matrix Limited.
6 February 2013
European Medicines Agency confirm Company’s qualification as SME.
11 December 2012
Manufacturing Services Agreement signed with manufacturer for the GMP manufacturing of Smart Matrix®.
13 January 2012
The Board of Smart Matrix Limited is pleased to announce the approval of its Investment Memorandum.
9 December 2011
The Board of Smart Matrix Limited is pleased to announce the commencement of trading, the establishment of its corporation framework and the receipt of £200,000 of equity funds.
15 September 2011
The Company receives advance assurance from HMR&C that it is a qualifying company for EIS purposes and that, providing the Company continues to meet its obligations in this regard, its shares will qualify for EIS relief.
18 April 2011
Date of incorporation of Smart Matrix Limited.